Safety Weight Loss Drugs LORCASERIN CAS 616202-92-7 for Fat Burning
Quick Details for LORCASERIN
Product Name: LORCASERIN
Synonyms: LORCASERIN;(R)-8-Chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine;Apd 356;Apd356;Apd-356;Ar-10a;Unii-637E494o0z;(1R)-8-Chloro-2,3,4,5-tetrahydro-1-Methyl-1H-3-benzazepine
Product Categories: Amines;Aromatics;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Boiling point : 288 ºC
Density : 1.075
Appearance : White crystalline powders
Usage : Diet pills . A novel selective 5-HT2C-receptor agonist for the treatment of obesity.
Weight loss drugs
Lorcaserin is a new drug for the treatment of obesity , belonging to oral potent selective serotonin 2C receptor agonists, lorcaserin hydrochloride is successfully developed by the US company Arena, on June 27, 2012 by the US FDA it is approved for marketing, as adjuvant therapy for obesity or merge with at least one weight-related complications in overweight adults in low-calorie diet and exercise basis . Clinical studies show that the drug can reduce weight of obesity and overweight patients ,it can improve obesity-related metabolic parameters, and it is well tolerated. Lorcaserin affinity for the 5-HT2c 100 times higher than the 5-HT2B (valvular heart disease risk) ,it has good safety,it is the first FDA-approved weight-loss drug after 1999 . In a year of Lorcaserin treatment, the average weight loss ranges from 3 to 3.7 percent.
Belviq(Lorcaserin hydrochloride) is an FDA-approved prescription weight-loss medication that, when used with diet and exercise, can help some overweight? adults with a weight-related medical problem, or obese adults, lose weight and keep it off. It is not known if BELVIQ when taken with other prescription, over-the-counter, or herbal weight-loss products is safe and effective. It is not known if BELVIQ changes your risk of heart problems, stroke, or death due to heart problems or stroke.
Belviq is a serotonin 2C receptor agonist. It hasbeen shown to decrease food consumption and promote satiety by selectivelyactivating serotonin 2C receptors in the brain.
Belviq is specifically indicated as an adjunct to a reduced-calorie diet andincreased physical activity for chronic weight management in clinically obeseadults (BMI of 30 kg/m2 or greater) and overweight adults (BMI of 27 kg/m2 orgreater) with at least one weight-related comorbid condition.
Belviq is supplied as a tablet designed for oral administration. The recommendeddose is one 10mg tablet twice daily. Use of Belviq should be discontinued if 5%weight loss is not achieved by week 12 of treatment.
Lorcaserin has good tolerability and safety, lorcaserin is used in non-diabetic patients, the most common adverse reactions are headache, dizziness, fatigue, nausea, dry mouth and constipation. This product is used in patients with diabetes, common adverse reactions are headache, back pain, cough, low blood sugar and fatigue.studies have found that lorcaserin and placebo are Similar in the proportion of serious adverse reactions, lorcaserin does not increase the incidence of valvular heart disease. After lorcaserin treatment , the incidence of depression is lower , the research shows that the proportion of depression led by lorcaserin 10mgbid, 10mgqd and placebo are 1.9%, 1.1% and 1.8%, emotional low incidence rates are 0.6%, 0.9% and 0.9%, the proportion of suicidal thoughts are 0.9%, 0.6% and 0.7% .the product is pregnancy X-class , pregnant women are disabled; whether this product is secreted by milk is unknown, breast-feeding women need to weigh on the use of the drug; this product is not recommended for children.